Alyeska Investment Group
ITCI

Alyeska Investment Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Alyeska Investment Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-451,146
Closed -$37.7M – 696
2024
Q4 		$37.7M Sell
451,146
-479,984
-52% -$39.4M 0.14% 178
2024
Q3 		$68.1M Sell
931,130
-463,402
-33% -$34.8M 0.35% 100
2024
Q2 		$95.5M Buy
1,394,532
+1,142,612
+454% +$79.2M 0.55% 46
2024
Q1 		$17.4M Buy
251,920
+133,137
+112% +$9.15M 0.11% 222
2023
Q4 		$8.51M Sell
118,783
-12,917
-10% -$743K 0.06% 273
2023
Q3 		$6.86M Buy
131,700
+93,700
+247% +$5.46M 0.05% 320
2023
Q2 		$2.41M Sell
38,000
-12,000
-24% -$748K 0.02% 399
2023
Q1 		$2.71M Buy
+50,000
New +$2.42M 0.02% 337
2021
Q1 		– Sell
-218,473
Closed -$6.95M – 848
2020
Q4 		$6.95M Sell
218,473
-337,839
-61% -$8.88M 0.1% 236
2020
Q3 		$14.3M Buy
556,312
+287,912
+107% +$6.57M 0.22% 149
2020
Q2 		$6.89M Sell
268,400
-209,026
-44% -$4.23M 0.1% 235
2020
Q1 		$7.34M Buy
+477,426
New +$10.4M 0.15% 158
2017
Q4 		– Sell
-548,955
Closed -$8.66M – 545
2017
Q3 		$8.66M Buy
+548,955
New +$8.06M 0.06% 255
2015
Q4 		– Sell
-50,000
Closed -$2M – 474
2015
Q3 		$2M Buy
50,000
+37,485
+300% +$1.22M 0.02% 330
2015
Q2 		$400K Sell
12,515
-6,393
-34% -$162K ﹤0.01% 462
2015
Q1 		$452K Sell
18,908
-38,945
-67% -$872K 0.01% 473
2014
Q4 		$1.02M Sell
57,853
-2,142
-4% -$33.5K 0.02% 396
2014
Q3 		$823K Sell
59,995
-65,498
-52% -$984K 0.02% 339
2014
Q2 		$2.12M Sell
125,493
-69,070
-36% -$1.14M 0.05% 308
2014
Q1 		$3.54M Buy
+194,563
New +$3.51M 0.1% 225

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Alyeska Investment Group's ITCI Position: Q1 2025 in Review

Alyeska Investment Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 451,146 shares — an estimated $37.7M sold.

Alyeska Investment Group first reported a position in ITCI in Q1 2014 and held it in 20 quarters. The position peaked at $95.5M in Q2 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Alyeska Investment Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 451,146 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $37.7M.
  • Alyeska Investment Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 20 quarters.
  • Alyeska Investment Group's Intra-Cellular Therapies Inc. position peaked at $95.5M in Q2 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Alyeska Investment Group's 13F filing for Q1 2025, filed 15 May 2025.